erlotinib hydrochloride has been researched along with Bright Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H; Domoto, Y; Hirakawa, Y; Honda, K; Miyashita, N; Nagase, T; Nakamura, M; Nangaku, M; Oda, Y; Oki, R | 1 |
| Chung, S; Fan, X; Harris, RC; Li, Y; Li, Z; Niu, A; Overstreet, JM; Wang, S; Wang, Y; Zhang, MZ | 1 |
| Koskinen, PK; Palin, N; Rintala, JM; Rintala, SE; Savikko, J | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
4 other study(ies) available for erlotinib hydrochloride and Bright Disease
| Article | Year |
|---|---|
Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glomerulonephritis; Hematuria; Humans; Kidney; Lung; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteinuria | 2022 |
Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes.
Topics: Albuminuria; Animals; Biomarkers; Crosses, Genetic; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Glomerulonephritis; Hypoglycemic Agents; Insulin Resistance; Kidney; Macrophages; Membrane Transport Modulators; Mice, Knockout; Mice, Mutant Strains; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Kinase Inhibitors; T-Lymphocytes; Transforming Growth Factor alpha | 2018 |
Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis.
Topics: Animals; Creatinine; ErbB Receptors; Erlotinib Hydrochloride; Glomerulonephritis; Isoantibodies; Kidney; Male; Rats; Rats, Wistar | 2016 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |